Pfizer Files Lasofoxifene NDA For Treatment Of Osteoporosis
This article was originally published in The Pink Sheet Daily
Executive Summary
Selective estrogen receptor modulator now is called Fablyn rather than Oporia, a name under which it received two “not approvable” letters.
You may also be interested in...
Pfizer Ready For Fablyn Vs. Evista Match, But FDA May Not Play Along
The long-term data from Pfizer's PEARL study are the firm's best bet for eking out a competitive distinction for its osteoporosis drug Fablyn against Lilly's Evista. FDA, however, seems less inclined to put those findings in labeling, particularly the breast cancer data
Pfizer Ready For Fablyn Vs. Evista Match, But FDA May Not Play Along
The long-term data from Pfizer's PEARL study are the firm's best bet for eking out a competitive distinction for its osteoporosis drug Fablyn against Lilly's Evista. FDA, however, seems less inclined to put those findings in labeling, particularly the breast cancer data
Pfizer/Ligand’s Osteoporosis Drug Fablyn Gets Advisory Committee Review
Lasofoxifene beats out Wyeth’s Viviant for first advisory committee review of the competing next-generation SERMs.